Saturday, November 25, 2006

Glaucoma 'the sneak thief of sight': Glaucoma Foundation leads campaign against eye disease - Health & Fitness

IT'S called "the sneak thief of sight," and it strikes African-Americans at a higher rate than any other race. In fact, a staggering I in every 13 Blacks has glaucoma--a total of about 1.5 million persons of all ages and conditions. Because of a prevalence of other risk factors, Blacks are four to six times more likely to develop the disease than Whites. Not only that, Blacks develop it on average 10 years earlier than Whites and are about 10 times more likely to go blind from it.
The disease, which has not received the attention and publicity of diseases like diabetes, heart disease, and hypertension, has taken the vision of some 120,000 people now living in the United States.
One of the major problems is that many people think glaucoma automatically leads to blindness. Although it is true that there is no cure and that vision impaired by the disease cannot be restored, the progression of the disease, if caught early and properly treated, can usually be halted and sight preserved for a lifetime. The New York-based Glaucoma Foundation, which is leading a national campaign for a greater understanding of the disease, says 90 percent of the people who are blind as a result of glaucoma lost their sight needlessly.
Dr. Kevin C. Greenidge, chairman of the Department of Ophthalmology at the SUNY Health Science Center at Brooklyn and a board member of the Glaucoma Foundation, says that there have been many advances in recent years in treating the disease. "We're finding that glaucoma may be a different disease in people of African descent requiring more aggressive therapies" he says. "Our main aim is to lower the pressure buildup within the eye to slow progression of the disease and save sight."
nyone, at any age, can develop glaucoma. Infants can be born with the disease, and it can develop in small children. The Glaucoma Foundation says 6 percent of the population over 65 has glaucoma. The more significant risk factors a person has the greater the likelihood that the disease will set in at an earlier age.
Dr. Greenidge says "diabetes is a risk factor, and hypertension is a risk factor, and being African-American is a risk factor--and if you have those three--there is a significant chance that you may develop glaucoma and you need to be checked on a regular basis. And if you add to that a family history of glaucoma, you probably have a 50-50 chance of getting glaucoma, if not greater."
A serious problem here is that people, particularly African-American people, wait too long to seek medical attention. "More than 80 percent of the patients who come into my office for the first time are already almost legally blind," he says. "The only thing we can do at that point is to prevent things from getting worse. We can never make it any better." Experts say people of all incomes and backgrounds wait too long before seeking treatment. "We're not talking about granny who just doesn't put on her reading glasses," Dr. Greenidge says. "We are talking about the movers and shakers of the world. Glaucoma happens so slowly and so insidiously that many times people don't realize they are losing their vision until the disease has progressed greatly."
To understand the danger and the need for early treatment, one must have some understanding of how the eye operates. Each eye is controlled by fibers that make up the optic nerve, which carry visual images to the brain. The front compartment of the eye is filled with a watery fluid that nourishes the cornea and the lens, providing them with oxygen and vital nutrients. The fluid also provides the necessary pressure to help maintain the shape of the eye. This pressure is called intraocular pressure. When this pressure is too high, it can put extreme pressure on the optic nerve, damaging it and leading to glaucoma. Most, but not all glaucoma diseases, are characterized by increased fluid pressure in the eye.
Because there are usually no early symptoms, glaucoma must be detected through a comprehensive and painless eye exam. During the exam, the doctor checks fluid pressure in the eyes, examines visions at various distances, and dilates pupils with drops to inspect the optic nerve. Corneal thickness is also measured, and, if needed, the patient's visual field will be checked to measure side vision.
In the early stages, glaucoma is usually treated with daily eye drops to lower the pressure on the eye. Eye drops can actually delay or prevent the onset of glaucoma in people with elevated eye pressure. When eye drops are ineffective, surgery may be needed.
When 72-year-old Louise Hackett was told she had glaucoma about 10 years ago, she was overwhelmed with emotion. "I cried," says the Washington, D.C., resident. "People treat you bad enough when you can see. Lord knows how they would treat you when you're blind."
But once the retired domestic worker realized that having glaucoma wasn't a death sentence or a guarantee that she would go blind, she took on the disease relentlessly. Her medical regimen includes regular doctor visits and eye drops three times a day. As a result, her vision has been stable for the last decade.


Access over 1 million songs - Yahoo! Music Unlimited.

Glaucoma Tour update

Glaucoma Tour update


Summary: Latest information about RNIB's major glaucoma awareness campaign including the response from MPs

A highly successful national glaucoma awareness campaign was held over the summer of 2005. This was launched at the House of Commons on 24 May and followed by a tour of 13 cities around the UK (Belfast, Birmingham, Bristol, Cardiff, Edinburgh, Glasgow, Leeds, Leicester, Liverpool, London, Manchester, Newcastle, Norwich). The campaign had three main elements, a shopping centre exhibition, professional's meetings and community meetings.
A ‘Glaucoma Advice Centre’ exhibition was held in local shopping centres where staff from RNIB and local blind societies were on hand to answer questions and distribute printed materials. Typically 250-300 people visited the stand at each location.
In each city, meetings with eye care professionals were held to discuss the latest developments in the delivery of care for patients with glaucoma. The meetings generated considerable discussion on improving services in each region by reducing waiting times for hospital appointments, improving medication compliance and accessing groups in the community at higher risk of glaucoma.
Meetings with community leaders were also held to highlight that people of African or African Caribbean descent and people with a family history are more likely to be affected by the condition.
Engaging politicians was also an important aspect of the campaign. A number of local MPs visited the stand including the Secretary of State for Health, Patricia Hewitt MP, who came to the Shires Shopping Centre in Leicester and met Steve Winyard, RNIB’s Head of Public Policy. Patricia Hewitt expressed concern at the long wait some glaucoma patients are experiencing for follow-up appointments and promised to take action.

Parliamentary launch

Our Glaucoma Tour and campaign to raise awareness of Glaucoma was launched at the House of Commons on 24 May. It was hosted by David Heath MP, Chair of the All Party Parliamentary Group on Eye Health and Visual Impairment. The event was highly successful with over fifty MPs attending and offering their support.
We also asked MPs to sign Early Day Motion 164 calling on the Government to increase publicity around the benefits that a regular eye test can have in detecting eye diseases such as glaucoma, leading to early intervention and the saving of sight. To date 112 MPs have added their names.

MPs' support

David Lepper MP

Brighton Pavilion MP David Lepper backs RNIB’s glaucoma campaign. David says “My personal reason for backing the campaign is that my brother has glaucoma so I know the importance of regular checks. I had a test for glaucoma in Brighton just two weeks ago and got the all-clear”
John Baron MP for Billericay and District said “The RNIB’s campaign deserves our fullest support because glaucoma can lead to blindness if not treated. I would urge everyone to have a regular sight test”

Andrew Stunell MP

Andrew Stunell MP said “Glaucoma can lead to blindness if it is not treated, and is the most common cause of preventable blindness in the UK. I am concerned that everyone in Stockport gets their eyes tested at least every two years. This helps to ensure that conditions like glaucoma are detected at an early stage, so people can get treated. I support RNIB’s campaign and wish them well with their national tour”

Annette Brook MP

Annette Brooke MP for Mid Dorset and Poole North also offered her support “200,000 people nationally have lost their sight through glaucoma and we need to do more to raise public awareness of the condition, especially amongst people with a family history of glaucoma, and people from African backgrounds, who are more at risk”

Peter Luff MP

Peter Luff MP for Mid Worcester helped back the campaign in Parliament and wants to see everyone have an eye test at least every two years. “We need to do more to raise public awareness of the condition” he said

Quiz machine

We also offered MPs the chance to test their awareness by taking part in our quiz machine. This asks six questions and offers three options for each answer. Although awareness among MPs was good, it is now better!

Shopping centres


Many hundreds of people as well as local MPs and MEPs have visited the shopping centre stand at the various locations we have already visited.
A couple in their 50s had heard the BBC radio interview and came along to the stand in Bristol. Both the mother and grandfather of the husband had glaucoma. He had not had his eyes tested since 1997 but left the stand to go and make an appointment with an optometrist.
A 72 year old man approached the stand and said he had not had an eye test for four years but after talking with us was going to go and have one that same day.
Children visit the stand
Children also visited the stand end enjoyed taking part in the quiz. They also experienced the effects of glaucoma to their sight.






Everyone is raving about the all-new Yahoo! Mail beta.

Catalyst For a Cure Campaign Sets Public Launch Sept 8

Catalyst For a Cure Campaign Sets Public Launch Sept 8
Roger McGuinn of The Byrds is GRF National Honorary Chairperson
Research Team Proves Collaboration Can Accelerate Discovery
SAN FRANCISCO, CA., Monday, August 15, 2005 – With a personal appearance by Roger McGuinn of the famed folk rock band The Byrds, the Glaucoma Research Foundation (GRF) launches the public phase of its $7.5 million Catalyst For a Cure campaign on Thursday, Sept. 8 from 6 pm to 8 pm at The City Club, 155 Sansome Street, San Francisco. Other features of the evening include an unveiling of features transforming www.glaucoma.org into a model of Internet accessibility for the vision impaired, and an update on research from H. Dunbar Hoskins, Jr., MD, a co-founder of the Glaucoma Research Foundation.
“I have glaucoma, the silent thief of sight,” said McGuinn, identified with timeless Byrds’ classics “Mr. Tambourine Man” and “Turn! Turn! Turn!”, will be the campaign’s Honorary National Chairperson and spokesperson. “I‘m coming to talk about my experience, the need for testing, and my hope that together we can speed the cure for glaucoma, once and for all.” McGuinn has created a new radio public service announcement with these messages for future release.
A primary focus of the campaign is GRF’s entrepreneurial Catalyst For a Cure (CFC) research collaboration, speeding the cure with two important innovations: departing from the academic model of sole scientists working in isolation by bringing together a team of four laboratories working in genuine real time collaboration, and by reaching into the burgeoning promise of neuroscience and genetics. Laboratory teams participating in the CFC collaboration are affiliated with Johns Hopkins University, University of Utah, University of Washington, and Vanderbilt.
Thomas M. Brunner, President & CEO of GRF explained that the campaign was launched last year, and immediately anchored with gifts of $2.5 million from members of the GRF board, reflecting a 260% increase in their personal giving. “Our board wants to send the strongest signal to the community of the urgent need to accelerate the pace of discovery, and the measurable progress this new approach is bringing.” Altogether, the campaign is at $4.2M, and just passing the 56% of goal mark.
“There is an epidemic of blindness coming,” points out H. Dunbar Hoskins Jr., MD, a co-founder of GRF along with Robert Shaffer, MD, and John Hetherington, MD. “We must get ahead of this, and that’s what GRF research and education programs are designed to do. Everyone, from infants to seniors, is vulnerable to glaucoma, though we think of glaucoma primarily as a disease of an aging population. The cutting edge approaches researchers are using challenge the aging process itself. This is a very exciting time!”
The Glaucoma Research Foundation is a national non-profit organization, receiving no government funding. Through research and education, our goal is to protect the sight and independence of people with glaucoma. For more information about glaucoma, contact the Glaucoma Research Foundation, 251 Post Street, Suite 600, San Francisco, CA 94108 or email GRFmediadesk@glaucoma.org.


Cheap Talk? Check out Yahoo! Messenger's low PC-to-Phone call rates.

Annette Brooke MP joins RNIB's national glaucoma and blindness awareness campaign

Annette Brooke MP joins RNIB's national glaucoma and blindness awareness campaign

6.00.00pm UTC (GMT +0000) Wed 25th May 2005
Annette Brooke MP today joined RNIB to launch their national glaucoma campaign in parliament. The campaign will see the charity touring 13 UK cities to raise public awareness of the condition that if undetected can lead to sight loss, without obvious symptoms in its early stages. Glaucoma can lead to blindness if not treated and is the most common cause of preventable blindness in the UK.
The MP for Mid Dorset and Poole North said "I am concerned that everyone in Mid-Dorset gets their eyes tested at least every two years to ensure that conditions like glaucoma are detected at an early stage and appropriate treatment undertaken. 200,000 people nationally have lost their sight through glaucoma and we need to do more to raise public awareness of the condition, especially amongst people with a family history of glaucoma, and people from African backgrounds, who are more at risk. I support RNIB's campaign and wish them well with their national tour".
Steve Winyard, RNIB's Head of Public Policy, said: "We are delighted Annette is supporting our campaign as it is hugely concerning that detection of glaucoma is so low and that so many people are needlessly losing their sight through what is essentially a treatable condition. That's why regular eye tests are so vital. An eye test can save your sight.
"People need to be aware that glaucoma does not necessarily have any symptoms and that once you do have the symptoms it's too late. Up to 40 per cent of useful sight can be lost before a person realises anything is wrong - but if caught early enough glaucoma can in nearly all cases be successfully treated and no sight need be lost."
THOUSANDS NEEDLESSLY GOING BLIND
A report published by RNIB today (1) to coincide with the campaign launch shows a shocking lack of awareness of glaucoma with one in five people having never heard of the condition. Only two per cent of people aware of glaucoma knew it could lead to "tunnel vision" and just three per cent knew it could have no symptoms. Also less than one in five people knew that people with glaucoma or those specifically at risk were eligible for free eye tests.
Steve Winyard continued: "The simple message to everyone is - have regular eye tests. An eye test can save your sight. This is even more important to people over 40 and those with a close relative with glaucoma as they are at higher risk. People of African origin are four times more likely to develop glaucoma.
"RNIB is calling on the Government to fund a major public education campaign to promote the importance of eye tests as vital health checks which ensure the early detection of eye disease and the prevention of blindness."
The campaign is supported by broadcaster Sir Trevor McDonald as well as other celebrities including writer and comedian Jenny Eclair and is launched today at a parliamentary event at the House of Commons. RNIB is also holding a series of seminars for health and social care professionals around the country and begins a 13-city UK "Roadshow" on 3 June where it will be holding exhibitions and providing information and advice to the public on glaucoma.
ENDS
Notes to Editors
1) Tunnel Vision, Steve Winyard, RNIB Campaign Report 24, May 2005. Survey carried out on behalf of RNIB by Taylor Nelson Sofres, Omnimas, 8 - 12 April 2005 with a sample of 1349 adults nationwide.
2) RNIB estimates that 216,000 people in the UK have a serious sight problem as a result of glaucoma (Tunnel Vision). The term serious sight problem means people with visual acuity less than 6/12 - this relates to a wide range of sight conditions from total blindness to not being able to see a friend across the street or read newsprint even with the aid of glasses.
3) You are entitled to free NHS eye tests if: you are aged 40 or over and have a close relative with diagnosed glaucoma, have diabetes or glaucoma, are aged 60 or over, are under 16, or under 19 and in full time education, you or your partner receive income support, family credit, income based job seekers allowance or disabled persons tax credit, are entitled to vouchers for complex lenses or if you are registered blind or partially sighted.


Everyone is raving about the all-new Yahoo! Mail beta.

Kirby Puckett Brings Glaucoma Campaign to San Francisco

Kirby Puckett Brings Glaucoma Campaign to San Francisco
Former Baseball All-Star Joins Mayor Willie Brown and
The Glaucoma Research Foundation for Glaucoma Awareness and Screening Program

SAN FRANCISCO, Oct. 27 /PRNewswire/ -- Former Minnesota Twins baseball
all-star Kirby Puckett, together with the Glaucoma Research Foundation and
Pharmacia & Upjohn, is bringing the national "Don't Be Blindsided!" glaucoma
education campaign to San Francisco. Mr. Puckett and Mayor Willie Brown are
among the speakers at a 12:30 p.m. press conference in Union Square to help
raise awareness about glaucoma and provide important information about the
condition. The Glaucoma Research Foundation will also offer free on-site
glaucoma screenings to the public from 11:30 a.m. to 1:30 p.m.
Today's event occurs in conjunction with the annual meeting of the
American Academy of Ophthalmology (AAO) in San Francisco. The AAO represents
the largest U.S. association of ophthalmologists and supports glaucoma
awareness programs throughout the country.
Glaucoma is a leading cause of blindness and vision loss in the United
States, affecting more than three million Americans, up to half of whom are
undiagnosed. Like Puckett, nearly 120,000 Americans each year lose all or
part of their vision to glaucoma. In California, there were nearly 200,000
cases of glaucoma reported in people over age 40, according to 1990
statistics.
"I am pleased to team up with Mayor Brown, the Glaucoma Research
Foundation and Pharmacia & Upjohn to convey the importance of early detection
of glaucoma to the community of San Francisco," said Puckett, whose baseball
career ended in 1996 because of vision loss caused by glaucoma. "Until I was
diagnosed, I never gave glaucoma a thought. Had I been aware of the
importance of regular glaucoma exams, I may have been able to save the sight
in my right eye. Thousands of Americans may be at risk for glaucoma, which is
why I challenge everyone to get regular eye exams."
San Francisco Mayor Willie Brown lauds the "Don't Be Blindsided!" campaign
because it addresses a health issue affecting many people locally as well as
nationally.
"Glaucoma doesn't attract much interest, yet it remains a serious health
threat to thousands of people here in California," said Mayor Brown. "Kirby
has done a wonderful job of raising awareness about glaucoma and getting
people to see their eye doctor."
Glaucoma is a complex group of eye disorders having a common feature of
optic nerve damage. Conditions commonly associated with glaucoma include
elevated intraocular pressure within the eye, cupping of the optic disc and
loss of visual field. The pressure comes from an inability of the eye to
drain the fluid properly. There are usually no symptoms.
"Americans need to know about the dangers of glaucoma," said Tara Steele,
Executive Director of the Glaucoma Research Foundation. "With Kirby Puckett's
involvement, we hope to make the public aware of the wealth of resources that
are available to people at risk, and the importance of following through to
protect your sight."
Although glaucoma can strike at any age, it is most commonly found in
people over age 40. African-Americans, people with diabetes and those with a
family history of glaucoma are at higher risk for developing the disease.
Once glaucoma is diagnosed, treatment may involve eye drops and laser or
conventional surgery to control intraocular pressure.
"Early diagnosis is key to glaucoma treatment," said Eve Higginbotham,
M.D., Professor and Chair, Department of Ophthalmology, University of Maryland
School of Medicine. "Because the disease has no symptoms in its early stages,
a painless and relatively quick examination by an eye doctor is the only way
to diagnose the disease early on, when appropriate treatment can minimize
vision loss."
"Don't Be Blindsided!" is a national glaucoma education campaign sponsored
by Pharmacia & Upjohn to educate Americans about the risks of glaucoma and the
need for periodic eye examinations from qualified eye care professionals. The
program encourages Americans to seek early detection of and treatment for
glaucoma. "Don't Be Blindsided!" events occur throughout the United States
and are supported by such organizations as the American Academy of
Ophthalmology and the Glaucoma Research Foundation.
The Glaucoma Research Foundation is a national voluntary health
organization dedicated to protecting the sight and independence of people with
glaucoma, through research and education. The Foundation's ultimate goal is
to find a cure for glaucoma.
Pharmacia & Upjohn (NYSE: PNU) is a global, innovation-driven
pharmaceutical and health care company. Pharmacia & Upjohn's products,
services and employees demonstrate its commitment to improve wellness and
quality of life for people around the world.


SOURCE Pharmacia & Upjohn

Friday, November 10, 2006

Immediate Treatment Helps Delay Progression Of Glaucoma

Immediate Treatment Helps Delay Progression Of Glaucoma


Researchers have found that immediately treating people who
have early stage glaucoma can delay progression of the
disease. This finding supports the medical community's
emerging consensus that treatment to lower pressure inside
the eye can slow glaucoma damage and subsequent vision
loss. These results are reported in the October 2002 issue
of "Archives of Ophthalmology."
Scientists found that immediate treatment of newly-
discovered primary open-angle glaucoma, the most common
form of glaucoma and one of the nation's leading causes of
vision loss, led to a slower rate of disease progression.
The findings from this study reinforce accumulating medical
evidence that lowering eye pressure in glaucoma's early
stages slows progression of the disease.
"These results strongly support the body of evidence
suggesting that immediate treatment of early stage, open-
angle glaucoma will slow the disease progression," said
Paul Sieving, M.D., Ph.D., director of the National Eye
Institute (NEI), one of the Federal government's National
Institutes of Health and co-sponsor of the study.
"Unfortunately, glaucoma has no early warning signs, and
many affected patients are unaware they have the disease
until it has advanced. Once people have lost vision from
glaucoma, it cannot be regained. However, early detection
and timely treatment would help to save the vision of
thousands of people each year."

Dr. Sieving also notes that the study results provide
important new medical knowledge on the course of the
disease, both among treated and untreated patients.
"Because most people are treated for glaucoma as soon as
they are diagnosed, little is known about the natural
history of the disease," he said. "Future reports from the
study will add further important information on glaucoma
progression and its risk factors."
The study -- called the Early Manifest Glaucoma Trial --
followed 255 patients, aged 50-80 years, with early stage
glaucoma in at least one eye. Most patients were identified
in a population screening. The average age of the patients
at the beginning of the study was 68 years. One group (129
patients) was treated immediately with medicines and laser
to lower eye pressure, and the other group (126 patients) -
the control group -- was left untreated. Both groups were
followed carefully and monitored every three months for
early signs of advancing disease, using indicators that are
extremely sensitive for detecting glaucoma progression. Any
patient in the control group whose glaucoma progressed was
immediately offered treatment.

After six years of followup, scientists found that
progression was less frequent in the treated group (45
percent) than in the control group (62 percent), and
occurred significantly later in treated patients. Treatment
effects were also evident in patients with different
characteristics, such as age, initial eye pressure levels,
and degree of glaucoma damage. In the treated group, eye
pressure was lowered by an average of 25 percent.
The study was a collaborative effort involving the
University of Lund, Sweden, with centers in Malm?,
Helsingborg, and Lund, Sweden, as well as Stony Brook
University, Stony Brook, New York.
These results should be put into perspective, according to
Anders Heijl, M.D., Ph.D., chairman of the Department of
Ophthalmology at Sweden's Malm? University Hospital and
first author of the report. "Although the study closely
checked for possible glaucoma progression, many of the
patients remained stable over time, even those in the
control group," Dr. Heijl said. "On the other hand, despite
the clear effect of treatment, glaucoma progressed in as
many as 30 percent of treated patients after four years."
Dr. Heijl said that the time it took for glaucoma to
progress varied greatly among patients and was sometimes
rather short, even in treated patients. "This shows that in
many patients with rapidly progressing glaucoma, the
treatment used in this study was insufficient to halt
progression of the disease," Dr. Heijl said.
Dr. Heijl emphasized that treatment for early, newly
diagnosed glaucoma should be individualized and carefully
balanced. Before deciding on the best treatment option, eye
care professionals should consider several unique patient
factors, such as age, eye pressure levels, and disease
severity. "The study findings support the medical
community's growing contention that glaucoma treatment
should be tailored to the individual needs of the patient,"
Dr. Heijl said. "One option could include no initial
treatment, but subsequent treatment if the disease
progresses. Many glaucoma medicines have side effects, so
the decision not to treat the disease in its early stage --
but closely monitor patients -- can postpone or obviate the
need for medications."
Although the study results confirm the belief that reducing
eye pressure is beneficial, "they do not prove that
elevated eye pressure in itself is the primary cause of
glaucoma," said M. Cristina Leske, M.D., chair of the
Department of Preventive Medicine at Stony Brook University
and a study co-author. "However, because reducing eye
pressure slows the progression of glaucoma, eye pressure
levels are important in the course of the disease."
Dr. Leske said that the study treatment had few side
effects. The most important was an increase in nuclear
opacities, a type of cataract, but the number of related
cataract surgeries in the treated group was small.
Open-angle glaucoma affects about 2.2 million Americans age
40 and over; another two million may have the disease and
don't know it. Glaucoma occurs when the optic nerve is
damaged. In most cases, increased pressure in the eye is a
risk factor for this damage. The damage to the optic nerve
causes loss of peripheral (side) vision, although people
are often unaware that they have glaucoma. As the disease
worsens, the field of vision gradually narrows and
blindness can result. However, if detected early through a
comprehensive eye exam, glaucoma can usually be controlled
and serious vision loss prevented.
The Early Manifest Glaucoma Trial was co-sponsored by the
Swedish Research Council. A list of EMGT study centers and
principal investigators is attached.
The National Eye Institute is part of the National
Institutes of Health (NIH) and is the Federal government's
lead agency for vision research that leads to sight-saving
treatments and plays a key role in reducing visual
impairment and blindness. The NIH is an agency of the U.S.
Department of Health and Human Services.


Everyone is raving about the all-new Yahoo! Mail beta.

Thursday, November 09, 2006

Glaucoma Awareness Month Emphasizes Treatments that Reduce Side Effects, Help Save Vision

udDuring Glaucoma Awareness Month in January, the National Eye Health Education Program (NEHEP) Partnership, coordinated by the National Eye Institute (NEI), is highlighting the medical advances for glaucoma that have been developed during the past five years.
"These therapies effectively treat glaucoma while at the same time greatly reducing side effects," said Jack A. McLaughlin, Ph.D, acting director of the NEI, one of the Federal government's National Institutes of Health.
Glaucoma, a leading cause of irreversible vision loss in the United States, is a disease that affects three million Americans, half of whom do not know they have it because of its lack of early symptoms. Advances in glaucoma treatment are only beneficial when the disease is detected early. By the time people realize they are losing vision, the vision they have already lost is gone forever. Those in higher risk groups should get a dilated eye exam ? in which drops are placed in the eye to dilate the pupils ? at least every two years. A dilated eye exam allows the eye care professional to obtain a better view of the eye's optic nerve to look for early signs of glaucoma. Higher risk groups include anyone over the age of 60; African Americans over the age of 40; and people who have a family history of glaucoma.
Two new glaucoma drugs ? latanoprost and dorzolamide ? based on NEI-supported research, "reduce unpleasant side effects, such as dry eyes and increased risk of retinal detachment," Dr. McLaughlin said. "The side effects from the older glaucoma treatments were major reasons why some glaucoma patients did not take their medications. The new therapies help preserve remaining vision and mark a significant step in improving the quality of life for people with glaucoma."
Glaucoma occurs when nourishing fluid that normally flows in and out of the eye drains too slowly. As the fluid builds up, the pressure inside the eye progressively increases. This leads to optic nerve damage and reduced peripheral (side) vision. As the disease worsens, the field of vision gradually narrows and blindness may result. However, if glaucoma is detected and treated early in its progression, it can usually be slowed and serious vision loss can be delayed.
Dr. McLaughlin also noted that NEI-supported research has shown that laser surgery is a safe and effective alternative to eye drops as a treatment for newly-diagnosed glaucoma. Laser surgery for glaucoma involves using a high energy beam of light to make tiny, evenly-spaced burns that open up the drainage area inside the eye, allowing for better outflow of the fluid. This procedure, often done in the doctor's office, requires only local anesthesia.
One of the more significant recent research findings was that Black and White patients with advanced glaucoma respond differently to two surgical treatments for the disease. Scientists found that Black patients with advanced glaucoma benefit more from a regimen that begins with laser surgery, and Whites patients benefit more from one that begins with an operation called a trabeculectomy. With this procedure, a small opening is made in the front chamber of the eye, providing a new drainage pathway for the fluid inside the eye. A trabeculectomy is done in an operating room and requires local or general anesthesia.
"This was the first evidence that unique patient characteristics could influence our therapeutic choices for glaucoma," said Eve Higginbotham, MD, chairperson of the NEHEP Planning Committee and chairperson of the Department of Ophthalmology at the University of Maryland. "Doctors now have better information to recommend treatment programs, depending on the patient's race, and give people with advanced glaucoma a better chance to preserve and prolong their vision." Glaucoma is three to four times as common in Blacks as in Whites, and blindness from glaucoma is six times more common in Blacks than in Whites.
Glaucoma Awareness Month is sponsored by the NEHEP Partnership, which represents public and private organizations dedicated to educating the public about the importance of preventive eye care.
The National Eye Institute (NEI) is part of the National Institutes of Health (NIH) and is the Federal government's lead agency for vision research. NEI-supported research leads to sight-saving treatments and plays a key role in reducing visual impairment and blindness. The NIH is an agency of the US Department of Health and Human Services.


Access over 1 million songs - Yahoo! Music Unlimited.

Friday, November 03, 2006

US Hosted World Sight Day Celebration October 10

US Hosted World Sight Day Celebration October 10


More Americans than ever are facing the threat of blindness
from age-related eye disease. More than one million
Americans aged 40 and older are currently blind and an
additional 2.4 million are visually impaired. These
numbers are expected to double during the next 30 years as
the Baby Boomer generation ages.
With the goal of making vision a public health priority
nationally and globally, the National Eye Institute (NEI),
one of the Federal government's National Institutes of
Health, joins the Lions Clubs International, Lighthouse
International, and the International Agency for the
Prevention of Blindness to host World Sight Day with the
Martin Luther King, Jr. Memorial Library in Washington,
D.C. on October 10, 2002.
Eve Slater, M.D., assistant secretary of health, U.S.
Department of Health and Human Services, kicks off the
celebration at a noon (EDT) event to highlight the
Department's dedication to the goals of World Sight Day and
its commitment to improving eye health for all Americans.

"World Sight Day is an annual observance that showcases
global commitment to prevent vision loss and blindness
through early detection, treatment, and rehabilitation,"
Dr. Slater said. "Promoting vision health and care is the
motivating force for the World Sight Day partners. We
stand with our partners here, and around the globe, to
demonstrate our determination in making vision a public
health priority."
World Sight Day was launched by Lions Clubs International
in 1998 to recognize and reinforce the importance of
eradicating preventable blindness. In the five years since
its inception, World Sight Day events, including cataract
and glaucoma screenings, collection of used eye glasses for
recycling, and distribution of educational material, have
been held on six continents.
"Few Americans realize that blindness is a major and
increasing problem in the United States," said J. Frank
Moore III, chairman, Lions Clubs International Foundation.
"Although Lions Clubs International has long been committed
to eradicating preventable and reversible blindness around
the world, we are focusing increased attention on working
with our partners to prevent blindness and vision loss in
the United States."
Lions Clubs International is marking World Sight Day by
launching a major initiative to combat vision loss and
diabetic retinopathy among Hispanics and others in
California. Lions are mobilizing screening units and
healthcare professionals to screen adults and children for
diabetes, diabetic retinopathy, and general vision problems
at the Montebello Senior Center (Alex Esquivel Center) in
Montebello, Calif. This will kick off a major area-wide
diabetic retinopathy program.
Lighthouse International, a leading resource on vision
impairment and vision rehabilitation worldwide, celebrates
its eighth annual National Vision Rehabilitation Day on
October 10 in concert with World Sight Day. National
Vision Rehabilitation Day is a public awareness campaign
designed to educate Americans about the prevalence of
vision impairment and the critical importance of vision
rehabilitation services, counseling, and training that help
people overcome the challenges associated with vision loss.
"Lighthouse International is honored to participate in
World Sight Day efforts to raise awareness about vision
loss and vision rehabilitation," said Barbara Silverstone,
D.S.W., president and CEO, Lighthouse International.
"Facing and coping with vision loss can be challenging and
overwhelming. We want people to know that there are
support and training services available in their
communities to help those affected by vision loss."
The International Agency for the Prevention of Blindness
(IAPB) is a coordinating, umbrella organization that leads
international efforts in mobilizing resources for blindness
prevention activities. IAPB works collaboratively with
more than 26 national and international organizations to
advance its mandate of combating avoidable blindness.
"Eighty percent of the world's blindness is preventable,
and that is the message we need to share on World Sight
Day," said Louis Pizzarello, M.D., M.P.H., chairman, IAPB
North American Region. "Vision loss and blindness have a
profound effect on quality of life for people worldwide.
By coming together to make vision a health priority, we are
taking action and changing lives for the better."
Coordinated and implemented through the World Sight Day
partners, this year's activities address visual impairment
from eye diseases and refractive errors, encourage regular
eye examinations for children and adults, and promote
vision rehabilitation.
World Sight Day provides an opportunity to promote healthy
vision in neighborhoods and communities with programs
adopted at the local, state, and national levels. In
keeping with its commitment to make vision a public health
priority in communities nationwide, NEI has instituted a
Healthy Vision 2010 Community Awards Program. Award
recipients will receive funding for community-based health
promotion projects designed to prevent vision loss and
blindness.
"The National Eye Institute is dedicated to promoting
visual health at the community level," said NEI director,
Paul A. Sieving, M.D., Ph.D. "Our Community Awards Program
and the model community events held during World Sight Day
help empower people at the local level to actively
participate in promoting and maintaining healthy vision."
To schedule day-of-event interviews, contact Michael
Coogan, NEI Office of Communication, at 301-496-5248 or by
email at mjc@nei.nih.gov. To find out more about World
Sight Day, the Healthy Vision 2010 Community Awards Program
or NEI, visit http://www.nei.nih.gov.
The NEI is part of the National Institutes of Health (NIH)
and is the Federal government's lead agency for vision
research that leads to sight-saving treatments and plays a
key role in reducing visual impairment and blindness. The
NIH is an agency of the US Department of Health and Human
Services.
World Site Day:


Want to start your own business? Learn how on Yahoo! Small Business.

Immediate Treatment Helps Delay Progression Of Glaucoma

Immediate Treatment Helps Delay Progression Of Glaucoma


Researchers have found that immediately treating people who
have early stage glaucoma can delay progression of the
disease. This finding supports the medical community's
emerging consensus that treatment to lower pressure inside
the eye can slow glaucoma damage and subsequent vision
loss. These results are reported in the October 2002 issue
of "Archives of Ophthalmology."
Scientists found that immediate treatment of newly-
discovered primary open-angle glaucoma, the most common
form of glaucoma and one of the nation's leading causes of
vision loss, led to a slower rate of disease progression.
The findings from this study reinforce accumulating medical
evidence that lowering eye pressure in glaucoma's early
stages slows progression of the disease.
"These results strongly support the body of evidence
suggesting that immediate treatment of early stage, open-
angle glaucoma will slow the disease progression," said
Paul Sieving, M.D., Ph.D., director of the National Eye
Institute (NEI), one of the Federal government's National
Institutes of Health and co-sponsor of the study.
"Unfortunately, glaucoma has no early warning signs, and
many affected patients are unaware they have the disease
until it has advanced. Once people have lost vision from
glaucoma, it cannot be regained. However, early detection
and timely treatment would help to save the vision of
thousands of people each year."

Dr. Sieving also notes that the study results provide
important new medical knowledge on the course of the
disease, both among treated and untreated patients.
"Because most people are treated for glaucoma as soon as
they are diagnosed, little is known about the natural
history of the disease," he said. "Future reports from the
study will add further important information on glaucoma
progression and its risk factors."
The study -- called the Early Manifest Glaucoma Trial --
followed 255 patients, aged 50-80 years, with early stage
glaucoma in at least one eye. Most patients were identified
in a population screening. The average age of the patients
at the beginning of the study was 68 years. One group (129
patients) was treated immediately with medicines and laser
to lower eye pressure, and the other group (126 patients) -
the control group -- was left untreated. Both groups were
followed carefully and monitored every three months for
early signs of advancing disease, using indicators that are
extremely sensitive for detecting glaucoma progression. Any
patient in the control group whose glaucoma progressed was
immediately offered treatment.

After six years of followup, scientists found that
progression was less frequent in the treated group (45
percent) than in the control group (62 percent), and
occurred significantly later in treated patients. Treatment
effects were also evident in patients with different
characteristics, such as age, initial eye pressure levels,
and degree of glaucoma damage. In the treated group, eye
pressure was lowered by an average of 25 percent.
The study was a collaborative effort involving the
University of Lund, Sweden, with centers in Malm?,
Helsingborg, and Lund, Sweden, as well as Stony Brook
University, Stony Brook, New York.
These results should be put into perspective, according to
Anders Heijl, M.D., Ph.D., chairman of the Department of
Ophthalmology at Sweden's Malm? University Hospital and
first author of the report. "Although the study closely
checked for possible glaucoma progression, many of the
patients remained stable over time, even those in the
control group," Dr. Heijl said. "On the other hand, despite
the clear effect of treatment, glaucoma progressed in as
many as 30 percent of treated patients after four years."
Dr. Heijl said that the time it took for glaucoma to
progress varied greatly among patients and was sometimes
rather short, even in treated patients. "This shows that in
many patients with rapidly progressing glaucoma, the
treatment used in this study was insufficient to halt
progression of the disease," Dr. Heijl said.
Dr. Heijl emphasized that treatment for early, newly
diagnosed glaucoma should be individualized and carefully
balanced. Before deciding on the best treatment option, eye
care professionals should consider several unique patient
factors, such as age, eye pressure levels, and disease
severity. "The study findings support the medical
community's growing contention that glaucoma treatment
should be tailored to the individual needs of the patient,"
Dr. Heijl said. "One option could include no initial
treatment, but subsequent treatment if the disease
progresses. Many glaucoma medicines have side effects, so
the decision not to treat the disease in its early stage --
but closely monitor patients -- can postpone or obviate the
need for medications."
Although the study results confirm the belief that reducing
eye pressure is beneficial, "they do not prove that
elevated eye pressure in itself is the primary cause of
glaucoma," said M. Cristina Leske, M.D., chair of the
Department of Preventive Medicine at Stony Brook University
and a study co-author. "However, because reducing eye
pressure slows the progression of glaucoma, eye pressure
levels are important in the course of the disease."
Dr. Leske said that the study treatment had few side
effects. The most important was an increase in nuclear
opacities, a type of cataract, but the number of related
cataract surgeries in the treated group was small.
Open-angle glaucoma affects about 2.2 million Americans age
40 and over; another two million may have the disease and
don't know it. Glaucoma occurs when the optic nerve is
damaged. In most cases, increased pressure in the eye is a
risk factor for this damage. The damage to the optic nerve
causes loss of peripheral (side) vision, although people
are often unaware that they have glaucoma. As the disease
worsens, the field of vision gradually narrows and
blindness can result. However, if detected early through a
comprehensive eye exam, glaucoma can usually be controlled
and serious vision loss prevented.
The Early Manifest Glaucoma Trial was co-sponsored by the
Swedish Research Council. A list of EMGT study centers and
principal investigators is attached.
The National Eye Institute is part of the National
Institutes of Health (NIH) and is the Federal government's
lead agency for vision research that leads to sight-saving
treatments and plays a key role in reducing visual
impairment and blindness. The NIH is an agency of the U.S.
Department of Health and Human Services.


Get your email and see which of your friends are online - Right on the new Yahoo.com

Thursday, November 02, 2006

Eye Drops May Delay or Prevent Glaucoma in African Americans at Higher Risk

Eye Drops May Delay or Prevent Glaucoma in African Americans at Higher Risk
Eye drops that reduce elevated pressure inside the eye can delay or possibly prevent the onset of glaucoma in African Americans at higher risk for developing the disease, researchers have found. This makes it more important to identify African Americans at higher risk for developing glaucoma so they can receive prompt evaluation for possible medical treatment. These results are reported in the June 2004 issue of Archives of Ophthalmology.

Study Findings

Scientists found that daily pressure-lowering eye drops reduced the development of primary open-angle glaucoma in African Americans by almost 50 percent. Primary open-angle glaucoma is the most common form of glaucoma and one of the nation's leading causes of vision loss. Of the African American study participants who received the eye drops, 8.4 percent developed glaucoma. By comparison, 16.1 percent of the African American study participants who did not receive the eye drops developed glaucoma. The study was funded by the National Eye Institute (NEI) and the National Center on Minority Health and Health Disparities (NCMHD), two components of the Federal government's National Institutes of Health.
The results of this study, called the Ocular Hypertension Treatment Study (OHTS), are a followup to initial results released two years ago. In those findings, researchers discovered that treating people with elevated eye pressure could delay or prevent the onset of glaucoma. At that time, results for the subgroup of African Americans trended in the same direction, but were not conclusive.

The Effects of Galucoma on Your Eyes

Primary open-angle glaucoma affects about 2.2 million Americans age 40 and over, half of whom are not aware they have the disease. Vision loss from glaucoma occurs when the optic nerve is damaged. In most cases, elevated eye pressure, also called ocular hypertension, contributes to this damage. This causes gradual loss of peripheral (side) vision. As the disease progresses, the field of vision gradually narrows and blindness can result. Glaucoma has no early symptoms, and by the time people experience problems with their vision, they usually have a significant amount of optic nerve damage. However, if detected early, glaucoma can usually be controlled and serious vision loss prevented. Comprehensive dilated eye examinations are recommended at least once every two years for African Americans over age 40 and all people over age 60.

Treatment Considerations

"This is the first study to recruit large numbers of African Americans to examine the benefit of pressure-lowering eye drops to prevent or delay the onset of glaucoma," said Paul A. Sieving, M.D., Ph.D., director of the NEI. "The results underscore that African Americans over age 40 should receive a comprehensive dilated eye exam at least once every two years to see if they are at higher risk for glaucoma."
These results do not imply that every African American with high eye pressure requires treatment, according to Eve Higginbotham, M.D., chair of the Department of Ophthalmology at the University of Maryland Medical Center and first author of the journal article. "When determining treatment, doctors should take into account several risk factors, including specific anatomical characteristics of the optic nerve and the cornea," Dr. Higginbotham said. "While African Americans participating in the study were more likely than others to have these specific physical characteristics, the study results underscore the importance of measuring these ocular risk factors rather than relying solely on the race or ethnicity of the individual."
Dr. Higginbotham suggested that before determining treatment, the doctor and patient should also discuss the patient's health status and life expectancy, and the burden of daily treatment, including cost, inconvenience, and possible side effects.

The Reality of Glaucoma Risks

Elevated eye pressure results when the fluid that flows in and out of the eye drains too slowly, gradually increasing pressure inside the eye. It is estimated that between three and six million people in the U.S. are at increased risk for developing primary open-angle glaucoma, representing between four and seven percent of the population above age 40. In this study, ocular hypertension was defined as pressure of 24 mm Hg or greater in at least one eye.
The OHTS studied more than 1600 people, including 408 African Americans, 40-80 years of age who had elevated eye pressure but no signs of glaucoma. Half were assigned daily pressure-lowering eye drops, and the other half were assigned to observation (no medication). In the medication group, the number of African Americans participants developing glaucoma was significantly lower (8.4 percent) compared to the observation group (16.1 percent).
"The study also confirms that the risk for developing glaucoma is higher among African Americans compared with others," said Michael Kass, M.D., of the Washington University Department of Ophthalmology and Visual Sciences and chair of the study. "A number of risk factors may be contributing to the increased prevalence of visual impairment from glaucoma in African Americans. These include a family history of glaucoma; earlier onset of the disease compared to other races; later detection of the disease; and economic and social barriers to treatment."

Coverage and Research

Glaucoma is a leading cause of blindness in African Americans, said John Ruffin Ph.D., director of the NCMHD. "Glaucoma is almost three times as common in African Americans than Whites," Dr. Ruffin said. "However, if glaucoma is detected and treated early in its progression, it can usually be slowed and serious vision loss can be delayed."
Dr. Ruffin said Medicare covers an annual dilated eye examination for people at higher risk for glaucoma. This important preventive benefit defines higher risk as people with diabetes; those with a family history of glaucoma; and African Americans aged 50 and older.
In addition to support from the NEI and NCMHD, the Ocular Hypertension Treatment Study was supported by Research to Prevent Blindness and Merck Research Laboratories. The study was conducted at 22 clinical centers across the country. A list of study centers and principal investigators is attached.
The National Eye Institute (NEI), the Federal government's lead agency for vision research, is part of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services. NEI-supported research leads to sight-saving treatments and plays a key role in reducing visual impairment and blindness.
The NIH's National Center on Minority Health and Health Disparities (NCMHD) conducts and supports research, training, information dissemination and other programs aimed at reducing the disproportionately high incidence and prevalence of disease, burden of illness, and mortality experienced by certain American populations, including racial and ethnic minorities and other groups with disparate health status, such as the urban and rural poor.


Low, Low, Low Rates! Check out Yahoo! Messenger's cheap PC-to-Phone call rates.